bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract B125: A culture of belonging in the pursuit of inclusive excellence
Authors: Nelson Joni , Shungu Nicholas , Harley Destiny 
Published: September 2024

Abstract
Significance: Over the past two decades, fostering diversity in the clinical and biomedical workforce has emerged as a best practice for improving cancer health outcomes and reducing cancer inequities. Cultivating a culture of belonging is a pivotal strategy for recruiting and retaining a diverse cancer workforce, particularly for individuals from underrepresented backgrounds. The Hollings Cancer Center (HCC) at the Medical University of South Carolina maintains a strategic aim to recruit, train, and develop a cancer workforce that reflects the diversity of the catchment area. In alignment with this aim, the HCC Office of Programs to Enhance Diversity (OPED) led a two-part forum that prioritized strategies to promote a culture of belonging. The forum included 1) a nationally renowned keynote speaker who detailed the significance of a culture of belonging and its intersections with recruitment and retention of a diverse cancer workforce and 2) table-top discussion with forum attendees intended to identify actionable initiatives that foster a culture of belonging. Methods: We utilized a quality improvement approach to explore opportunities to advance a culture of belonging within the HCC infrastructure. To assess the impact of the forum we conducted a descriptive analysis on attendee feedback surveys and thematic analysis of table-top discussions. Results: 34 forum attendees completed the evaluation survey. 97% of respondents felt that the forum was a good use of their time and 85% of respondents reported the information presented in the forum helped them reflect on their own sense of belonging. Two primary themes emerged from the table-top discussions: the pursuit of systematic approaches for fostering inclusivity and ensuring feasible pathways for diverse recruitment and retention. Additionally, the forum was a critical strategy for yielding key recommendations from attendees regarding actionable steps needed to foster a culture of belonging (e.g. use of welcome videos, mechanisms for addressing microaggressions, targeted recruitment advertisements, and establishment of affinity groups). Conclusion: In this presentation, we will delineate strategic pathways forward for the ongoing cultivation of a culture of belonging in the pursuit of inclusive excellence within the cancer workforce.
Citation Format: Joni Nelson, Nicholas Shungu, Destiny Harley. A culture of belonging in the pursuit of inclusive excellence [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B125.
Abstract B145: County-level food insecurity and hepatocellular carcinoma risk: A cross-sectional analysis
Authors: Kehm Rebecca D. , Vilfranc Chrystelle L. , McDonald Jasmine A. , Wu Hui Chen 
Published: September 2024

Abstract
This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR002) of the Conference Program/Proceedings.
Citation Format: Rebecca D. Kehm, Chrystelle L. Vilfranc, Jasmine A. McDonald, Hui Chen Wu. County-level food insecurity and hepatocellular carcinoma risk: A cross-sectional analysis [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B145.
Abstract B153: Social and Structural Influences of Preventive Cancer Screenings for Native Hawaiian and Pacific Islander Adults in Hawaiʻi
Authors: Willingham Mark L. , Cassel Kevin , Zhang Wei , Diaz Tressa P. , Sy Angela , Pagano Ian , Ta'afaki Munirih R. , Mummert Angelina G. 
Published: September 2024

Abstract
This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR012) of the Conference Program/Proceedings.
Citation Format: Mark L. Willingham Jr., Kevin Cassel, Wei Zhang, Tressa P. Diaz, Angela Sy, Ian Pagano, Munirih R. Ta'afaki, Angelina G. Mummert. Social and Structural Influences of Preventive Cancer Screenings for Native Hawaiian and Pacific Islander Adults in Hawaiʻi [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B153.
Abstract B177: Association between ethnicity and ovarian cancer tumor characteristics in Asian Americans in California
Authors: Lee Alice W. , Chang Jenny , Siddiqui Sannia , Ziogas Argyrios , Bristow Robert E. 
Published: September 2024

Abstract
Background: Ovarian cancer is often associated with poor survival given that most patients are diagnosed at advanced stages when treatment is less effective. The disease is also very heterogeneous, consisting of various histologic subtypes that each have distinct epidemiologic and pathologic profiles. Given that some studies have noted ethnic-specific disparities in ovarian cancer survival when the Asian American population is disaggregated and certain tumor characteristics are associated with more favorable outcomes, we examined the relationship between Asian ethnic subgroup and ovarian cancer disease presentation. Methods: We included a total of 31,230 non-Hispanic White and Asian/Pacific Islander ovarian cancer cases diagnosed between 1996 and 2020 from the California Cancer Registry. Multivariable logistic regression with odds ratios (ORs) and 95% confidence intervals (CIs) was used to examine the likelihood of being diagnosed with tumors of a certain stage, grade, and histologic subtype, for each Asian ethnic subgroup compared to non-Hispanic Whites. Demographic and socioeconomic factors were considered in the analyses. Results: Most, but not all, Asian ethnic subgroups were less likely to be diagnosed with advanced stage ovarian cancer and more likely to be diagnosed with clear cell ovarian cancer compared to non-Hispanic Whites. For South East Asians, the odds of having advanced stage tumors were 43% lower than non-Hispanic Whites (OR=0.57, 95% CI 0.41-0.79) and the odds of having clear cell tumors were almost 200% higher than non-Hispanic Whites (OR=2.97, 95% CI 1.92-4.61); only South Asians did not show lower odds of an advanced stage tumor diagnosis (OR=1.06, 95% CI 0.86-1.29) and higher odds of a clear cell tumor diagnosis (OR=0.93, 95% CI 0.63-1.37). Conclusion: There are clear differences in ovarian cancer disease presentation when each Asian ethnic subgroup is examined separately with South Asians constituting the only subgroup who did not show a lower likelihood of an advanced stage diagnosis and a higher likelihood of a clear cell diagnosis when compared to non-Hispanic Whites. Given that tumor stage and histologic subtype are considered important prognostic factors for ovarian cancer, identifying the underlying factors that may contribute to being diagnosed with certain tumor characteristics could provide clues to help us improve the survival of this highly fatal malignancy.
Citation Format: Alice W. Lee, Jenny Chang, Sannia Siddiqui, Argyrios Ziogas, Robert E. Bristow. Association between ethnicity and ovarian cancer tumor characteristics in Asian Americans in California [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B177.
Abstract B178: Examining ovarian cancer survival by Asian American ethnic subgroup: An analysis of California Cancer Registry data
Authors: Lee Alice W. , Chang Jenny , Siddiqui Sannia , Ziogas Argyrios , Bristow Robert E. 
Published: September 2024

Abstract
Background: Ovarian cancer is the leading cause of death among gynecologic malignancies. However, outcomes are not the same for all women with studies showing Asian Americans having the highest survival across all major racial groups. Since the Asian American population is heterogeneous, we examined ovarian cancer survival by Asian ethnic subgroup using data from the California Cancer Registry. Most ovarian cancer survival studies evaluate Asian Americans as a single aggregated group, which may mask important ethnic-specific disparities. Methods: A total of 31,230 ovarian cancers diagnosed among non-Hispanic Whites and Asian/Pacific Islanders between 1996 and 2020 were included in the analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the risk of dying from ovarian cancer comparing the Asian ethnic subgroups to non-Hispanic Whites using Cox proportional hazards models. The survival analyses also considered demographic, tumor, socioeconomic, and treatment characteristics. Results: For most Asian ethnic subgroups, risk of dying from ovarian cancer was comparable to non-Hispanic Whites with the only exception being Other Asians who showed a statistically significant 15% decreased risk of ovarian cancer death (HR=0.85, 95% CI 0.73-0.97, p-value=0.02). Another notable finding was the increased risk of death observed among Pacific Islander ovarian cancer patients when compared to non-Hispanic White patients (HR=1.27, 95% CI 0.99-1.62, p-value=0.06). Conclusion: Although most studies show Asian Americans having the highest ovarian cancer survival, our analyses indicate that only Other Asians have better survival and Pacific Islanders may have poorer survival relative to non-Hispanic Whites, highlighting the importance of disaggregation in future studies. These ethnic-specific disparities that were observed even after accounting for relevant survival-related characteristics should be further explored as it may inform important biological and behavioral factors associated with survival, which are not captured in cancer registry data.
Citation Format: Alice W. Lee, Jenny Chang, Sannia Siddiqui, Argyrios Ziogas, Robert E. Bristow. Examining ovarian cancer survival by Asian American ethnic subgroup: An analysis of California Cancer Registry data [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B178.
Abstract C015: Unraveling the structure of the Philadelphia chromosome using super-resolution microscopy
Authors: Dewson Gabrielle S. , Nir Guy 
Published: September 2024

Abstract
Philadelphia-positive leukemia is characterized by the translocation t(9;22)(q34;q11), which results in the oncogene BCR-ABL1 and a chromosome called the Philadelphia (Ph) chromosome (chr). The Philadelphia chromosome is best characterized in Chronic Myeloid Leukemia (CML); however, the translocation is also found in Acute Lymphoblastic Leukemia (ALL). Philadelphia-positive ALL has been historically understudied, especially in minority populations. Genome organization is a highly complex process by which chromatin is segregated within the nucleus into specific domains, making stable translocations highly unfavorable. How translocations are stabilized has been historically understudied. Here, we aim to examine how the Ph chr is stabilized and be the first to visualize an entire abnormal chr with high spatial and genomic resolution at the single-cell level. Using OligoSTORM, a super-resolution microscopy technique, we aim to image the entirety of the Ph chr at a nanoscale resolution in both CML and ALL cell lines. In addition to the DNA super-resolution trace, we have designed an RNA library to image a series of RNAs from the Ph chr on the same sample as the DNA trace, allowing us to connect the transcriptional data to the chromatin structure. We have successfully traced the entirety of the Ph chr. We have preliminary data suggesting that chr9 and chr22 segregate close to each other in non-leukemia healthy cells. We have also proven that our library design and methodology work to achieve the primary 500kb resolution. Preliminary data suggests that chr9 and chr22 in cells, that don’t typically have a Ph chr, segregate within proximity to translocate successfully. This study aims to compare the 3D structure of CML, ALL and non-leukemia cell lines to potentially identify genome organization-based biomarkers for identify and targeting the Philadelphia chromosome.
Citation Format: Gabrielle S. Dewson, Guy Nir. Unraveling the structure of the Philadelphia chromosome using super-resolution microscopy [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C015.
Abstract C016: Optical Techniques to Democratize Intravital Quantification of Metabolic Heterogeneity
Authors: Sunassee Enakshi 
Published: September 2024

Abstract
Since metabolic and vascular adaptations are essential for tumor cell survival, a technique capable of tracking metabolic heterogeneity at both the bulk tumor and cellular scales over extended timelines is necessary. To address this technological need, we have developed a multi-scale optical microscope relying on exogenous fluorescent reporters for dynamic spatiotemporal imaging of major metabolic pathways in vivo. This microscope utilizes a low-cost CMOS detector and LEDs for excitation to enable fluorescence microscopy in resource-limited settings. Here, we implement our system to assess changes in bulk tumor and cellular metabolic heterogeneity as vasculature is perturbed. 4T1 breast tumor-bearing mice were treated with combretastatin A-1 (a vascular disruptor), implanted with window chambers, and temporally imaged (n=5/group). Fluorescence imaging and Gabor filter/Djikstra segmentation approaches enabled metabolic and vascular analyses, respectively. We demonstrated the system’s ability to acquire co-registered images of vasculature, morphology, and distinct metabolic endpoints reporting on glucose uptake, fatty acid uptake, and mitochondrial metabolism at both wide-field and high resolutions. At 12 hours post-treatment, the tumors’ metabolism shifted from mitochondrial respiration to glycolysis in avascular regions. Further, we report a higher average vascular density in untreated versus treated mice at 108 hours post-treatment (p&lt;0.05, Kolmogorov-Smirnov test). On exploring the relationship between metabolic activity and vasculature, regions with high local tortuosity in the untreated group exhibited a higher reliance on fatty acid uptake than high tortuosity regions in the treatment group, indicating these cells’ reliance on fatty acids within a complex vascular network. Our multiplexed imaging strategy enables the quantification of tumor metabolism and vasculature over multiple length scales, which could be leveraged to study adaptations following clinical therapies.
Citation Format: Enakshi Sunassee. Optical Techniques to Democratize Intravital Quantification of Metabolic Heterogeneity [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C016.
Abstract C028: Effects of co-treatment with polyisoprenylated cysteinyl amide inhibitors and sotorasib on cell viability and ras signaling pathways in an African American lung cancer cell line
Authors: Mensah-Mamfo Justin K. , Ofosu-Asante Kweku 
Published: September 2024

Abstract
Lung adenocarcinoma (LUAD) is the most prevalent type of lung cancer among Blacks/African Americans(B/AAs) and all other racial and ethnic groups. Therapies that directly target mutant KRAS, the most common driver of LUAD, have been difficult to develop. Anti-cancer drugs such as Sotorasib, a KRASG12C inhibitor, were developed to treat cancers driven by the mutant KRAS protein. Nevertheless, recent studies have highlighted the limitations of Sotorasib as a viable long-term treatment due to intrinsic changes in cells, resulting in resistance and relapse. Polyisoprenylated Cysteinyl Amide Inhibitors (PCAIs) are novel anti-cancer agents developed to target hyperactive G-proteins such as KRAS, RHOA, CDC42 and RAC1 by disrupting their polyisoprenylation-dependent interactions. Previous work, using lung adenocarcinoma cell lines NCI-H23, derived from a B/AA male patient, revealed that PCAIs induce apoptosis in cells while inhibiting cell migration and invasion by 82%. Furthermore, the PCAI treatment induced hyperphosphorylation of the MAP kinase proteins MEK1/2, ERK1/2, p90RSK and AKT in the PI3K/AKT pathway. Current experiments seek to explore the effects of co-treatment with PCAIs and Sotorasib on cell viability and phosphorylation of MAP kinase proteins. Cell viability studies indicate increased potency when cells are co-treated with PCAIs and Sotorasib compared to treatments with individual compounds. The EC50 obtained for individual treatments of PCAI NSL-AB-51 and Sotorasib were 2.7 mM and 19 mM, respectively. The EC50 obtained for the treatments with varying concentrations of NSL-AB-51 combined with 18 mM Sotorasib, and varying concentrations of Sotorasib combined with 2.7 mM NSL-AB-51 were 1.8 mM and 10 mM, respectively. Preliminary western blot data indicates that the PCAIs induce the hyperphosphorylation of the MAP kinase pathway kinases MEK1/2, ERK1/2, and p90RSK. However, introduction of Sotorasib reverses the PCAI-induced hyperphosphorylation. Ongoing work is aimed at elucidating the interplay between PCAIs and Sotorasib with respect to cell viability and growth signaling pathway activations using cell lines with different KRAS mutations.
Citation Format: Justin K. Mensah-Mamfo, Kweku Ofosu-Asante. Effects of co-treatment with polyisoprenylated cysteinyl amide inhibitors and sotorasib on cell viability and ras signaling pathways in an African American lung cancer cell line [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C028.
Abstract C030: The Wip1 phosphatase activator QGC-8-52 selectively sensitizes p53-deficient cancer cells to chemotherapy
Authors: Wu Ke , Wu Yong , Vadgama Jay , Chen Qiao-Hong , Huang Zhi-min , Li Qun 
Published: September 2024

Abstract
PP2C serine-threonine phosphatase Wip1 is vital for tissue homeostasis, stress signaling, and the pathogenesis of various diseases, making it a promising target for cancer therapy. Inhibiting Wip1's expression or activity is a novel strategy to prevent cancer. However, traditional Wip1 suppression may not work in cancers lacking p53. Here, we evaluated a new Wip1 activator, QGC-8-52, in preclinical breast cancer models. QGC-8-52 sensitizes p53-deficient cancer cells to chemotherapy by facilitating Wip1-FOXO3a interaction and dephosphorylation of Thr487, which enhances FOXO3a's activity on the proapoptotic TRAIL gene. This effect is specific to p53-deficient cancer cells. In normal cells, Wip1 activation reduces drug-induced apoptosis by weakening upstream signaling to p53. Thus, activating Wip1 during chemotherapy boosts apoptosis in p53-negative tumors and protects normal tissues. Our findings highlight Wip1 activation as a potentially effective and safe treatment for p53-deficient cancers.
Citation Format: Ke Wu, Yong Wu, Jay Vadgama, Qiao-Hong Chen, Zhi-min Huang, Qun Li. The Wip1 phosphatase activator QGC-8-52 selectively sensitizes p53-deficient cancer cells to chemotherapy [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C030.
Abstract C039: Nativity and breast cancer outcomes by breast cancer subtype in the ENCLAVE Study
Authors: Kroenke Candyce , Aoki Rhonda , Alexeeff Stacey , Gomez Scarlett , Caan Bette , Morey Brittany , Torres Jacqueline , Kushi Larry 
Published: September 2024

Abstract
Background: Associations of nativity and breast cancer (BC) mortality are mixed in studies using cancer registry data. We examined associations in diverse women with detailed individual-level data on BC treatment and subtype. Methods: The study population included 5,718 Asian (n=722, 71% foreign-born), Hispanic (n=631, 42% foreign-born), and non-Hispanic White (n=4,365, 9% foreign-born) women from the ENCLAVE Study diagnosed with invasive BC from 1996-2013 using pooled, harmonized data from two (of three) cohorts with data on BC subtype. Data on nativity, reproductive and behavioral factors were self-reported from questionnaires; data on disease severity, BC subtype (luminal A, luminal B, Her2 expressing, triple negative breast cancer), treatment, and mortality were obtained from cancer registries and electronic health records. Recurrences were identified by recurrence algorithms and medical record review. We fit Cox proportional hazards regression models to examine associations between self-reported nativity and recurrence, BC-specific mortality, and overall mortality. Covariates included age, sociodemographic factors, disease severity, and treatment, reproductive and behavioral factors. We also examined associations by race, ethnicity, and BC subtype. Results: Compared to US-born women, foreign-born women had lower total mortality (hazard ratio [HR]=0.75, 95% confidence interval [CI]: 0.64-0.89); lower risks were suggested for recurrence (HR=0.85, 95% CI: 0.68-1.06) and breast cancer-specific mortality (HR=0.87, 95% CI: 0.66-1.14). Stratified by BC subtype, foreign- (vs. US-) born women had a lower risk of overall mortality among those with luminal A (HR=0.72, 95% CI: 0.56-0.92) and luminal B (HR=0.66, 95% CI: 0.48-0.91) but not other subtypes. Among women with luminal B BC, these associations reached statistical significance for recurrence (HR=0.65, 95% CI: 0.45-0.94) and BC-specific mortality (HR=0.53, 95% CI: 0.33-0.84). We noted no associations in other BC subtypes though analyses of less common subtypes were underpowered. Associations did not differ by race or ethnicity. Conclusion: Foreign-born women with BC had lower risk of overall mortality than US-born women. Risks of recurrence and BC-specific mortality were lower in foreign-born vs. US-born women among those with the luminal B BC subtype. Associations were not explained by behavioral or reproductive factors.
Citation Format: Candyce Kroenke, Rhonda Aoki, Stacey Alexeeff, Scarlett Gomez, Bette Caan, Brittany Morey, Jacqueline Torres, Larry Kushi. Nativity and breast cancer outcomes by breast cancer subtype in the ENCLAVE Study [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C039.